ArticleAmerican journal of hematology2026
Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.
Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03932643 (A Phase 1 Trial of ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After an Allogeneic Hematopoietic Stem Cell Transplant), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Trial of ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After an Allogeneic Hematopoietic Stem Cell Transplant
Who cites it
1 citing paper in PubMed.
- Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.American journal of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dordaviprone is a first-in-class small-molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell transplantation (HCT) for high-risk acute myeloid leukemia (AML) and myelodysplastic neoplasm (MDS). In a Phase I trial (n = 20), adults with high-risk AML or MDS received escalating doses of oral dordaviprone administered weekly for up to 13 four-weekly cycles (ClinicalTrials.gov ID: NCT03932643). The primary objective was to determine the rate of dose-limiting toxicities (DLTs) and grade ≥ 3 adverse events (AEs). Participants' characteristics included a median age of 68 years (range: 39-75 years) and high-risk features such as adverse-risk AML (50%) or very poor-risk MDS (75%), TP53 mutations (36%), or measurable residual disease before HCT (41% of AML). A total of 10 patients (one unevaluable) received 250-500 mg weekly doses, whereas the remaining 10 patients received 625 mg weekly doses. Patients received a median of 8.5 cycles (range: 1-13) of dordaviprone. No DLTs or graft failures were noted. Grades 3-4 acute GVHD was noted in 5%. Grade ≥ 3 AEs occurred in 45% (15% related). Grade 3-4 cytopenias were infrequent: anemia (15%), neutropenia (10%), and thrombocytopenia (15%). At 2 years, relapse-free survival and overall survival were 60% (95% confidence interval [CI]: 42%-86%) and 70% (95% CI: 53%-93%), respectively. Posttransplant dordaviprone maintenance was determined to be safe with low rates of cytopenias and promising efficacy in this high-risk population.
trial registrationClinicalTrials.gov identifier: NCT03932643.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.